Japan-based Daiichi Sankyo Company Limited and Sarah Cannon Research Institute, a subsidiary of HCA Healthcare, have dosed the first patient in a first-in-human phase 1/2 study assessing DS-7300, an investigational B7-H3 targeting antibody drug conjugate, intended to treat patients with various advanced solid tumours that have progressed on standard treatments or for whom no standard treatment exists, it was reported on Friday.
The study is the first in the strategic oncology collaboration between both firms, intended to accelerate and optimise global clinical development of Daiichi Sankyo's novel antibody drug conjugates and other targeted cancer therapies by merging the operational and scientific expertise of both organisations.
The product is the fourth antibody drug conjugate in clinical development using Daiichi Sankyo's proprietary DXd technology and it was designed to target and deliver chemotherapy inside cancer cells that express the B7-H3 protein, which is frequently overexpressed in various types of cancers and has been associated with disease progression and poor prognosis in many tumour types.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886